Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Transdermal Skin Patch Market Sales Size Opportunity To Reach US$ 18 Billion By 2026 With 100 Skin Patches In Clinical Pipeline Trials

This image opens in the lightbox

News provided by

Kuick Research

10 Sep, 2020, 05:27 GMT

Share this article

Share toX

Share this article

Share toX

- Kuick Research Report Highlights Ongoing Commercial Market Opportunity & Clinical Pipeline Trials Insight on  More Than 100 Patches By Company, Drug Class & Indication

NEW DELHI, Sept. 10, 2020 /PRNewswire/ -- "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026"

Report Highlights:

  • Global Transdermal Patch Market Forecast: > US$ 18 Billion by 2026
  • Number of Transdermal Patch in Clinical Pipeline: 100 Patches In Trials
  • Comprehensive Clinical Insight on 66 Commercially Available Transdermal Patches
  • Global Transdermal Patch Clinical Trials Insight by Company, Drug Class, Indication & Patent Information
  • Regional Trends & Market Insight: US, Europe & Asia-Pacific
  • Dosage & Price Insight on Transdermal Patch
  • Global Transdermal Patch Market Future Prospects
  • 350 Page Analysis On All Aspects Related To Market

Download Report: https://www.kuickresearch.com/report-global-transdermal-patch-market,-dosage,-price-and-clinical-trials-insight-2026.php

The transdermal patch market is associated with the development of a medicated patch that can get placed on the skin for the delivery of specific dose of drug or medication through the skin into the bloodstream of the patient. Further, this mode of treatment provides and promotes healing to the injured area of the body. There are several advantages that are associated with the transdermal drug delivery route over oral or intravenous mode of delivery is that it provides controlled release mode of medication to the patient, generally through body heat.

At the present scenario, transdermal patch of drug is considered as one of the most promising methods of drug delivery application. It has been only few years since the arrival of this mode of delivery for the drugs but the market has been experiencing increasing number of drugs being added to the list of therapeutic drugs that can get delivered through patches into the systemic circulation. Transdermal patch market is providing numerous other advantages too that is however making this drug delivery choice a preferable one. Among all, the most important advantage associated with the market is that it avoids the first-pass metabolism by the liver, which is apparently a big reason for the failure of most of the conventional dosage forms of injections and tablets.

The exposure of the drug at pre-defined rate in the body with respect to the disease condition is able to completely transform the landscape the transdermal patch market and dominate all the other topical and subcutaneous market. The non-invasive delivery of the drug via attractive proposition administered equal and even better application of the drugs inside the body, leading to complete eradication of the diseased cells. All these indicates at the opportunity that the market is providing to expand to product line extensions for novel drugs that will be entering the market. The complete research and development sector is poised towards tapping the hidden potential applications of the market and molding it to a huge and potent deliverable for the patient population.

As per the "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" report findings for Transdermal patch market, it is estimated that the arrival of drug patches for the patients has helped the researchers, physicians and the clinicians to transform the unstructured healthcare forum into a structured one by helping the researchers to more concentrate on the controlled release of the drug inside the body leading to less chance of developing severe side effects. From a very long period of time, the researchers have been extracting the benefits of transdermal patches over the other drugs and with time, the real implications of transdermal patches got extracting, leading to make the market as one of the dominating mode of drug delivery. The development of transdermal patch in the therapeutics sector is estimated to play quite pivotal role in improving the patient quality of life to much extent.

Table of Contents

1. Prologue to Transdermal Patch

  1.1 Overview of Transdermal Patch

  1.2 Relevance of Transdermal Patch

2. Types of Transdermal Patches

  2.1 Single/ Multiple-Layer Drug-in-Adhesive

  2.2 Reservoir Transdermal Patches

  2.3 Matrix Based Transdermal Patches

  2.4 Vapor Patch

  2.5 Active and Passive Patch

3. Mechanism of Transdermal Patch Drug Delivery

  3.1 Properties of Transdermal Therapeutics

  3.2 Components of Transdermal Patch

  3.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch

  3.4 Transdermal Patch v/s Traditional Drug Delivery Methods

4. Global Transdermal Patch Market Insight

  4.1 Global Market Scenario

  4.2 Regional Market Trends

    4.2.1 United States

    4.2.2 Europe

    4.2.3 Asia Pacific

5. Transdermal Patches for Cardiovascular Diseases - Availability, Dosage & Price Analysis

  5.1 Clonidine Transdermal Patch (Catapres–TTS)

  5.2 Nitro Glycerin Transdermal Patch

6. Opioid Drug Containing Transdermal Patches - Availability, Dosage & Price Analysis

  6.1 Fentanyl Transdermal Patch (Duragesic)

  6.2 Buprenorphine Transdermal Patch (Butrans Patch)

7. Transdermal Patches for Neurological Disorders - Availability, Dosage & Price Analysis

  7.1 Selegiline Transdermal Patch (Emsam)

  7.2 Scopolamine Transdermal Patch (Transderm-Scop)

  7.3 Rivastigmine Transdermal Patch (Exelon)

  7.4 Methylphenidate Transdermal Patch (Daytrana)

8. Transdermal Patch in Hormonal Therapy - Availability, Dosage & Price Analysis

  8.1 Estradiol Transdermal Patch

    8.1.1 Alora

    8.1.2 Vivelle-Dot

  8.2 Testosterone Transdermal Patch (Androderm)

  8.3 Ethinyl Estradiol & Norelgestromin Transdermal Patch (Xulane)

9. Transdermal Patches for Other Conditions - Availability, Dosage & Price Analysis

  9.1 Nicotine Transdermal Patch (Nicoderm CQ)

  9.2 Oxybutynin Transdermal Patch (Oxytrol)

10. Global Transdermal Patch Clinical Pipeline Overview

  10.1 By Phase

  10.2 By Region/Country

  10.3 By Drug Class/Molecule

  10.4 By Company

  10.5 By Orphan & Fast Track Status

  10.6 By Mode of Action

11. Global Patch Clinical Pipeline By Company, Indication & Phase

  11.1 Unknown

  11.2 Research

  11.3 Preclinical

  11.4 Clinical

  11.5 Phase-I

  11.6 Phase-I/II

  11.7 Phase-II

  11.8 Phase-III

  11.9 Preregistration

  11.10   Registered

12. Marketed Transdermal Patch Clinical Insight

13. Global Transdermal Patch Market Dynamics

  13.1 Favorable Market Parameters

  13.2 Commercialization Challenges

14. Global Transdermal Patch Market Future Outlook 2026

15. Competitive Landscape

  15.1 3M Pharmaceuticals

  15.2 Acrux

  15.3 Agile Therapeutics

  15.4 Allergan

  15.5 ANI Pharmaceuticals

  15.6 Antares Pharma

  15.7 Bayer HealthCare Pharmaceuticals

  15.8 Corium International

  15.9 Chase Pharmaceuticals

  15.10 DURECT Corporation

  15.11 Endo Pharmaceuticals

  15.12  Fempharm

  15.13 Hisamitsu Pharmaceutical

  15.14 Immune Pharmaceuticals

  15.15  Imprimis Pharmaceuticals

  15.16 Ipsen Bioscience

  15.17 Johnson & Johnson

  15.18 LaSalle Laboratories

  15.19  Lavipharm-increase

  15.20  MINRAD International

  15.21 NeurogesX

  15.22 Noven Pharmaceuticals

  15.23  NuPathe

  15.24 Nuvo Research

  15.25 Novartis

  15.26  Pain Therapeutics

  15.27  ProStrakan

  15.28 Purdue Pharma

  15.29  Sanofi

  15.30  Scilex Pharmaceuticals

  15.31 Senju Pharmaceutical

  15.32 Somerset Pharmaceuticals

  15.33 Teikoku Seiyaku

  15.34 Therapeutic Discovery Corporation

  15.35 Transdermal Delivery Solutions Corp

  15.36  UCB

  15.37  Xel Pharmaceuticals

  15.38  Zosano Pharma

Contact:
Neeraj Chawla
neeraj@kuickresearch.com
+91-9810410366

Logo: https://mma.prnewswire.com/media/1245952/Kuick_Research_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.